![](https://sp-ao.shortpixel.ai/client/to_auto,q_lossy,ret_img,w_1024,h_606/https://www.developox.com/wp-content/uploads/2020/09/opk-1024x606.jpg)
Its time to buy Opko Health (NASDAQ: OPK). The stock technical indicates it’s oversold and is in the buy zone. The Fundamental for OPKO Health are pretty strong with the company recently announcing it will start phase 2 clinical trials of Rayaldee. Coupled with that the revenue generated from covid testing done by Biorefrence labs makes Opko health a great long and short term investment. Recommended strong buy under $3.20